HER2-positive breast cancer: Beyond trastuzumab Journal Article
| Authors: | Murphy, C. G.; Fornier, M. |
| Article Title: | HER2-positive breast cancer: Beyond trastuzumab |
| Abstract: | The outlook for patients with HER2-positive breast cancer was revolutionized by the development of trastuzumab (Herceptin), a humanized murine monoclonal antibody. Use of this agent led to improved overall survival when it was added to chemotherapy for the treatment of metastatic breast cancer. Improved understanding of mechanisms of resistance to trastuzumab has facilitated the development of novel agents for HER2-positive breast cancer, and also resulted in superior outcomes when added to chemotherapy in the adjuvant setting. This review explores the use of several such agents, including lapatinib (Tykerb), HSP90 inhibitors, T-DM1, and other tyrosine kinase inhibitors. Emerging data from trials of these agents indicate that the HER2 pathway remains a valid therapeutic target following disease progression on trastuzumab, and suggest a promising role for combined HER2 blockade with two or more agents. |
| Keywords: | cancer survival; treatment response; unclassified drug; clinical trial; fatigue; neutropenia; review; sorafenib; bevacizumab; placebo; sunitinib; advanced cancer; cancer combination chemotherapy; cancer growth; diarrhea; hypertension; monotherapy; side effect; capecitabine; paclitaxel; cancer adjuvant therapy; comparative study; anorexia; metastasis; drug eruption; multiple cycle treatment; breast cancer; bleeding; nausea; stomatitis; thrombocytopenia; vomiting; epidermal growth factor receptor 2; practice guideline; protein tyrosine kinase inhibitor; drug dose escalation; hair color; molecular mechanics; cancer regression; cardiotoxicity; heat shock protein 90 inhibitor; tanespimycin; sepsis; headache; trastuzumab; mammalian target of rapamycin inhibitor; navelbine; drug dose regimen; heart left ventricle ejection fraction; everolimus; lapatinib; drug conjugation; maytansine; neratinib; pertuzumab; afinitor; hypertransaminasemia; lapatinib plus pazopanib; t dm 1 |
| Journal Title: | Oncology (Norwalk) |
| Volume: | 24 |
| Issue: | 5 |
| ISSN: | 0890-9091 |
| Publisher: | C M P Medica LLC * The Oncology Group |
| Date Published: | 2010-04-30 |
| Start Page: | 410 |
| End Page: | 415 |
| Language: | English |
| PROVIDER: | scopus |
| PUBMED: | 20480738 |
| DOI/URL: | |
| Notes: | --- - "Cited By (since 1996): 3" - "Export Date: 20 April 2011" - "CODEN: OCLGE" - "Source: Scopus" |
Citation Impact
Related MSK Work